QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
CVE:IPA

ImmunoPrecise Antibodies Ltd. (IPA.V) Stock Forecast, Price & News

C$19.64
+0.16 (+0.82 %)
(As of 01/26/2021 03:59 PM ET)
Add
Compare
Today's Range
C$18.91
Now: C$19.64
C$19.64
50-Day Range
C$0.19
MA: C$17.47
C$24.00
52-Week Range
C$2.75
Now: C$19.64
C$26.25
Volume38,772 shs
Average Volume57,813 shs
Market CapitalizationC$329.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

MarketRank

Overall MarketRank

0.38 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-8060626
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$16.70 million
Cash FlowC$0.96 per share
Book ValueC$1.85 per share

Profitability

Miscellaneous

Market CapC$329.21 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
C$19.64
+0.16 (+0.82 %)
(As of 01/26/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPA News and Ratings via Email

Sign-up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmunoPrecise Antibodies Ltd. (IPA.V) (CVE:IPA) Frequently Asked Questions

How has ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock been impacted by COVID-19?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock was trading at C$0.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IPA shares have increased by 2,590.4% and is now trading at C$19.64.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than ImmunoPrecise Antibodies Ltd. (IPA.V)?

Wall Street analysts have given ImmunoPrecise Antibodies Ltd. (IPA.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunoPrecise Antibodies Ltd. (IPA.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ImmunoPrecise Antibodies Ltd. (IPA.V)'s next earnings date?

ImmunoPrecise Antibodies Ltd. (IPA.V) is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for ImmunoPrecise Antibodies Ltd. (IPA.V)
.

How were ImmunoPrecise Antibodies Ltd. (IPA.V)'s earnings last quarter?

ImmunoPrecise Antibodies Ltd. (IPA.V) (CVE:IPA) posted its earnings results on Monday, December, 21st. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm earned $4.76 million during the quarter.
View ImmunoPrecise Antibodies Ltd. (IPA.V)'s earnings history
.

Who are some of ImmunoPrecise Antibodies Ltd. (IPA.V)'s key competitors?

What other stocks do shareholders of ImmunoPrecise Antibodies Ltd. (IPA.V) own?

Who are ImmunoPrecise Antibodies Ltd. (IPA.V)'s key executives?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Independent Chairman (Age 56)
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Dr. Yasmina Noubia Abdiche Ph.D., Chief Scientific Officer
  • Dr. Stefan Lang, Chief Bus. Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Ms. Lauren Smith, VP of Marketing and Sales

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock symbol?

ImmunoPrecise Antibodies Ltd. (IPA.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IPA."

How do I buy shares of ImmunoPrecise Antibodies Ltd. (IPA.V)?

Shares of IPA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock price today?

One share of IPA stock can currently be purchased for approximately C$19.64.

How big of a company is ImmunoPrecise Antibodies Ltd. (IPA.V)?

ImmunoPrecise Antibodies Ltd. (IPA.V) has a market capitalization of C$329.21 million and generates C$16.70 million in revenue each year.

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s official website?

The official website for ImmunoPrecise Antibodies Ltd. (IPA.V) is immunoprecise.com.

How can I contact ImmunoPrecise Antibodies Ltd. (IPA.V)?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s mailing address is 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada. The company can be reached via phone at +1-604-8060626.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.